Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 30 x 25 mg |
|
||
|
Film Coated Tablets 30 x 100 mg |
|
16003 | 5756 |
|
Film Coated Tablets 30 x 150 mg |
|
15996 | 5755 |
Related information
Dosage
Non-Small Cell Lung Cancer
The recommended daily dose of Erlotinib is 150 mg taken at least one hour before or two hours after the ingestion of food.
Pancreatic cancer
The recommended daily dose of Erlotinib is 100 mg taken at least one hour before or two hours after the ingestion of food, in combination with gemcitabine.
Please refer to the license holder for further details.
Indications
NSCLC (non-small cell lung cancer):
* First line treatment in patients with locally advanced or metastatic NSCLC if the cancer cells express mutations in EGFR.
* Maintenance treatment in patients with locally advanced or metastatic NSCLC if the cancer cells express mutations in EGFR and the disease remains largely unchanged after initial chemotherapy treatment.
* Treatment of patients with locally advanced or metastatic NSCLC if at least one previous chemotherapy treatment was unsuccessful in stopping the disease.
Pancreatic cancer:
* First line treatment in patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Contra-Indications
Hypersensitivity to erlotinib or to any of the excipients
Special Precautions
Please refer to the license holder for further details
Side Effects
Please refer to the license holder for further details
Drug interactions
Please refer to the license holder for further details
Pregnancy and Lactation
Please refer to the license holder for further details
Overdose
Please refer to the license holder for further details
